Published in final edited form as:

Cell Mol Life Sci. 2009 December ; 66(24): 3951–3966. doi:10.1007/s00018-009-0156-6.

THE PDZ2 DOMAIN OF ZONULA OCCLUDENS -1 AND -2 IS A PHOSPHOINOSITIDE BINDING DOMAIN

Kris Meerschaert^{1,2,6,*}, Moe Phyu Tun^{3,6}, Eline Remue^{1,2,6}, Ariane De Ganck^{1,2}, Ciska Boucherie^{1,2}, Berlinda Vanloo^{1,2}, Gisèle Degeest⁴, Joël Vandekerckhove^{1,2}, Pascale Zimmermann⁴, Nitin Bhardwaj⁵, Hui Lu⁵, Wonhwa Cho³, and Jan Gettemans^{1,2}

¹Department of Medical Protein Research, VIB, B-9000 Ghent, Belgium

²Department of Biochemistry, Ghent University, Faculty of Medicine and Health Sciences, Albert Baertsoenkaai 3, B-9000 Ghent, Belgium

³Department of Chemistry, University of Illinois, Chicago, Illinois 60607-7061, USA

⁴Department of Human Genetics, K.U. Leuven, Belgium

⁵Department of Bioengineering, University of Illinois, Chicago, Illinois 60607-7061, USA

Abstract

Zonula occludens proteins (ZO) are Postsynaptic density protein-95 Discs large-Zonula occludens (PDZ) domain-containing proteins that play a fundamental role in the assembly of tight junctions (TJ) and establishment of cell polarity. Here we show that the second PDZ domain of ZO-1 and ZO-2 binds phosphoinositides (PtdInsP) and we identified critical residues involved in the interaction. Furthermore, peptide and PtdInsP binding of ZO PDZ2 domains are mutually exclusive. Although lipid binding does not seem to be required for plasma membrane localisation of ZO-1, phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P₂) binding to the PDZ2 domain of ZO-2 regulates ZO-2 recruitment to nuclear speckles. Knockdown of ZO-2 expression disrupts speckle morphology, indicating that ZO-2 might play an active role in formation and stabilisation of these subnuclear structures. This study shows for the first time that ZO isoforms bind PtdInsPs and offers an alternative regulatory mechanism for the formation and stabilisation of protein complexes in the nucleus.

Keywords

tight junction; phospholipid; Post synaptic density-Discs large-Zona occludens; nucleus; cell polarity

Introduction

Many cellular processes involve multi-protein complexes which are formed and stabilised through multiple protein-protein interactions. In recent years, protein-lipid interactions have been shown also to contribute to the targeting and stabilisation of these complexes at specific cellular locations [1]. Of particular interest are the interactions with mono- and

Address correspondence to: Jan Gettemans, Department of Medical Protein Research, Flanders Interuniversity Institute for Biotechnology, Ghent University, Faculty of Medicine and Health Sciences, Albert Baertsoenkaai 3, B-9000 Ghent, Belgium. Tel: +3292649340. Fax: ++3292649490. jan.gettemans@ugent.be. Wonhwa Cho, Department of Chemistry (M/C 111), University of Illinois at Chicago, 845 West Taylor Street, Chicago, Illinois 60607-7061; TEL: 312-996-4883; FAX: 312-996-0431; wcho@uic.edu.
*Current address: Ablynx nv, Technologiepark, 9052 Ghent/Zwijnaarde, Belgium.

⁶These authors contributed equally to this paper.

polyphosphorylated derivatives of phosphatidylinositol (PtdIns), collectively known as phosphoinositides (PtdInsP). These lipids concentrate at the cytoplasmic face of cellular membranes and serve both a structural and a signalling role via their recruitment of proteins that contain PtdInsP-binding domains [2]. They also play a role as precursors of several types of second messengers. Deregulation of the metabolism of these lipids has been implicated in several disease processes, highlighting their physiologic importance [3,4]. Most studies on PtdInsP regulatory mechanisms have centred on cytoplasmic processes. However, PtdInsP and their biosynthetic machinery are also present in the nucleus [5].

Phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5) P_2) is the most abundant PtdInsP that plays a pivotal role in many physiological processes, ranging from regulation of membrane trafficking to formation of stress fibers and focal adhesions, apoptosis, chemotaxis, vesicle trafficking and gene expression [6]. In addition, the products of phosphoinositide 3-kinases (PI3K), PtdIns(3) P , PtdIns(3,4) P_2 and PtdIns(3,4,5) P_3 have been implicated in intracellular trafficking, signalling, mitogenesis and actin rearrangements [5,7]. Recent evidence also suggests involvement of PtdInsP in the establishment of cell polarity with PtdIns(4,5) P_2 and PtdIns(3,4,5) P_3 acting respectively as key determinants of the apical and basolateral surface [8,9].

An important protein complex required for the establishment of cell polarity in epithelial cells are the tight junctions (TJs). TJs function both as a barrier and a fence and contain both integral and peripheral membrane proteins, which are involved in the regulation of cytoskeletal organisation, establishment of polarity, and signalling to and from the nucleus [10]. One important class of such proteins are the zonula occludens proteins, ZO-1, ZO-2 and ZO-3, which are members of the membrane-associated guanylate kinase (MAGUK) protein family [11,12]. ZOs are peripherally associated membrane proteins that interact together and anchor membrane proteins like claudins, occludin and junctional adhesion molecule (JAM) to the actin cytoskeleton, and cluster diverse kinases, phosphatases, small G proteins and nuclear and transcription factors at the TJ [13].

ZO-1 and ZO-2 also concentrate in the nucleus in response to chemical stress or mechanical injury, or when cells are cultured at sparse density [14–16]. They also contain several nuclear localisation and export signals (NLS and NES) [17]. In confluent monolayers ZO-2 is observed at TJs while in sparse cultures it concentrates in the nucleus where it displays a speckled distribution and colocalises with the splicing factor SC35 [15]. It is also present in the nuclear matrix and associates with lamin B1 and actin [18]. The nuclear localisation of ZO-2 suggests that ZO-2 might play a role in nuclear processes, such as transcription and splicing. In this context, ZO-1 and ZO-2 have been shown to associate with proteins involved in the regulation of cell proliferation such as the transcription factors Jun, Fos, C/EBP [19], ZONAB [20] and KyoT2 [21]. Furthermore, ZO-2 has also been shown to modulate AP-1-regulated gene transcription [22].

We and others have shown that several PDZ domains bind PtdInsP, including PtdIns(4,5) P_2 , thereby identifying PDZ domains as potential PtdInsP binding domains [23,24]. Here we report that the PDZ2 domain of ZO-1 and ZO-2 belongs to a growing family of PtdInsP-binding PDZ domains. We measured the interaction of the PDZ2 domain and mutants with PtdInsPs in considerable detail by various biochemical assays. Collectively, this study provides new evidence for the existence of a subfamily of PDZ domains that are able to bind PtdInsP and offers an additional regulatory mechanism for the formation and stabilisation of protein complexes in the nucleus.

Materials and Methods

Materials

1-Palmitoyl-2-oleoyl-*sn*-glycero-3-phosphocholine (POPC), 1-palmitoyl-2-oleoyl-*sn*-glycero-3-phosphoserine (POPS), and 1-palmitoyl-2-oleoyl-*sn*-glycero-3-phosphoethanolamine (POPE) were from Avanti Polar Lipids (Alabaster, AL). (Poly)phosphoinositides were from Cayman (Ann Arbor, MI). Phospholipid concentrations were determined by a modified Bartlett analysis [25]. The Liposofast microextruder and 100-nm polycarbonate filters were from Avestin (Ottawa, Ontario). Fatty acid-free bovine serum albumin was from Bayer, Inc. (Kankakee, IL). Pioneer L1 sensor chip was from Biacore AB (Piscataway, NJ).

Antibodies and plasmids

Rabbit and mouse anti-ZO-1/2 were from Invitrogen (Merelbeke, Belgium). Anti-GST was from Amersham. The anti-PtdIns(4,5)P₂ 2C11 antibody was a kind gift of Dr. G Schiavo (Molecular Neuropathobiology, Cancer Research UK London Research Institute, UK); a commercial anti-PtdIns (4,5)P₂ IgM was obtained from Echelon. GFP-tagged human ZO-1 was a kind gift of Dr. H. Wunderli-Allenspach (Zurich, Switzerland). HA-tagged wild type canine ZO-2 (HA-ZO2 WT) in the CMV expression vector GW1 was a kind gift of Dr. Javier (Baylor College of Medicine, Houston, USA). Mouse ZO-2 cDNA was a gift from Dr. Tsukita (Osaka University, Japan) and was cloned in the pEGFP-C1 vector. Deletion constructs PDZ1-3 and SH3-C-terminus and the single PDZ domains and their mutants were cloned in the pEGFP-C1 and pGEX5×1 or pGEX 2TK vector.

Mutagenesis and Protein Expression

Mutagenesis of the PDZ2 domain of ZO-1 and -2 was performed using the Quikchange Mutagenesis kit (Stratagene). Plasmids were transformed into BL21(DE3) pLys cells for protein expression. BL21(DE3) cells were grown at 37 °C in LB medium containing 50 µg/ml ampicillin. Protein expression was induced with at 37°C for 4 h with IPTG. The PDZ2 domains used for monolayer and SPR measurements were expressed as glutathione-S-transferase (GST)-fusion proteins and purified by glutathione-Sepharose affinity chromatography. Protein concentrations were determined by the method of Bradford [26] using bovine serum albumin as a standard.

Cell culture

HeLa, MDA MB 231 and MDCK cells were maintained in Dulbecco's modified Eagle's medium + Glutamax (DMEM; Invitrogen), supplemented with 10% fetal bovine serum (FBS; Invitrogen), 100 U/ml penicillin and 0.1 mg/ml streptomycin. For MCF7-AZ cells, we used a mixture (1/1) of HAM F12 (Invitrogen) and DMEM + Glutamax with the same supplements as mentioned above.

RNAi — siRNAs specific for human ZO-2 were obtained from Eurogentec (Seraing, Belgium). The following sequences were used: sense siRNA sequence 1: 5'-GACCGCAUGUCCUACUUAAdTdT-3', antisense sequence 1: 5'-UUAAGUAGGACAUGCGGUCdTdT-3', sense sequence 2: 5'-GGAGAGACGUCAUCAGUAUdTdT-3' and antisense sequence 2: 5'-AUACUGAUGACGUCUCUCCdTdT-3'.

HeLa and MCF7 cells were transfected with siRNA duplexes (200 nM) at 80% confluency using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. A negative control siRNA duplex obtained from Eurogentec (Seraing, Belgium) was used under similar conditions. Seventy-two hours following transfection, the cells were harvested.

Staining and microscopy

Cultured cells were grown on glass coverslips, washed with PBS and fixed with 3% paraformaldehyde. After permeabilisation with 0.1 % Triton X-100 in PBS, cells were blocked in 1% BSA in PBS and incubated at 37°C with primary antibody for 1h or overnight at 4°C, followed by Alexa Fluor-488 goat anti-rabbit IgG (Molecular Probes, Eugene, OR) for 30 min at room temperature. Nuclei were stained using 4'-6-Diamidino-2-phenylindole (DAPI) (0.4 µg/ml) (Sigma).

For staining of plasmamembrane PtdIns(4,5)P₂ with the 2C11 antibody we adopted the protocol from Hammond et al. [27]. In short, cells were fixed for 3 hours at 4°C with ice cold 4% paraformaldehyde/0.2% glutaraldehyde. Cells were rinsed three times with 50mM NH₄Cl and simultaneously permeabilised and blocked for 4 hours at 4°C in 0.5% saponin, 5% normal goat serum (NGS, Sigma) and 50 mM NH₄Cl in sodium glutamate buffer (NaGB). Next, cells were incubated overnight at 4°C with primary antibody solution (2C11 1/100, 0.1% saponin, and 5% NGS in NaGB). After washing with NaGB, the secondary antibody was added (Alexa Fluor-594-anti mouse IgM 1/200, 0.1% saponin and 5% NGS in NaGB) for 4 hours at 4°C. Before mounting with Vectashield, cells were post-fixed for 10 minutes on ice and 5 minutes at room temperature. For staining of plasmamembrane PtdIns(4,5)P₂ in MDCK cells we used a protocol from Hammond et al. [28]. Cells were fixed for 15 min with 8% paraformaldehyde. Cells were rinsed three times with 50mM NH₄Cl and then left on ice for two minutes. Afterwards the cells were simultaneously permeabilised and blocked for 45 minutes at 4°C in buffer A (137 mM NaCl, 2.7 mM KCl and 20 mM Na-PIPES, pH 6.8) supplemented with 0.5% saponin, 5% NGS and 50 mM NH₄Cl. Next, cells were incubated for 1hr with primary antibody solution (2C11 1/200, 0.1% saponin, and 5% normal goat serum in buffer A). After washing with buffer A, the secondary antibody was added (Alexa Fluor-594-anti mouse IgM 1/200, 0.1% saponin and 5% NGS in buffer A) for 45 minutes at 4°C. Before mounting with Vectashield, cells were post-fixed for 10 minutes on ice and 5 minutes at room temperature with 2% PFA and washed for 3 times with 50mM NH₄Cl. Stained cells were examined using an Apotome Zeiss Axioplan II epifluorescence microscope. Images were captured using a cooled CCD Axiocam Camera and Axiovision 4.4 software (Zeiss, Göttingen, Germany).

Western blotting

Cells were disrupted in ice-cold lysis buffer (20 mM Tris-HCl pH 7.5, 150 mM NaCl, 1% Triton-X100, 1 mM PMSF) and a protease inhibitor cocktail mix (Roche Diagnostics, Mannheim, Germany). Insoluble material was removed by centrifugation (20,000×g for 15 min at 4°C). Western blotting was performed as described [29]. Proteins were visualised by enhanced chemiluminescence detection (ECL, Amersham Pharmacia Biotech, Buckinghamshire, UK).

Lipid-plate binding assay

Binding of GST-tagged proteins to PIP strips or GST-tagged proteins to PIP plates® (Echelon Biosciences Inc.) was done as described by the manufacturer. Briefly, GST proteins (10 nM) were incubated for 1h at room temperature with the preblocked plates. The plate was then washed 3 times with PBS containing 0.1% Tween-20 and incubated for 1h at room temperature with horseradish peroxidase-conjugated anti-GST (Amersham Biosciences). The bound proteins were detected using the TMB Microwell Peroxidase Substrate System (Kirkegaard & Perry Laboratories). Absorbance was determined at 450 nm using a microplate reader.

Peptide Synthesis, Immobilisation, and Binding Experiments

Connexin 43 (Cx43) C-terminal peptide (NH₂.PSSRASSRASSRPRPDDLEI.OH) was synthesised and purified according to established procedures [24]. The peptide was coupled to CNBr-activated Sepharose 4B (Pharmacia Biotech) at 5–7 mg/ml according to the manufacturer's protocol. For peptide-plate assays, the peptide (1 µg) was spotted in 96-well microtiter plates (Maxisorp, Nunc) and dried at 37°C for 1h. Blocking was done with 1% bovine serum albumin in phosphate-buffered saline (PBS) for 1h. GST fusion proteins (1 µM) in PBS were incubated for 1h at room temperature, and subsequently the wells were washed three times with PBS containing 0.1% Tween-20. The amount of bound protein was determined by a colorimetric reaction using HRP-conjugated anti-GST antibodies (Amersham Biosciences) and TMB substrate (Kirkegaard & Perry Laboratories).

Surface plasmon resonance (SPR) measurements

All SPR measurements were performed at 23 °C using a lipid-coated L1 chip in the BIACORE X system as described previously [30]. Briefly, after washing the sensor chip surface with running buffer (20 mM HEPES, pH 7.4, 0.16 M KCl), POPC/POPE/POPS/PtdInsP (37:40:20:3) and POPC/POPE (60:40) vesicles were injected at 5 ml/min to the active surface and the control surface (typically 5 to 10 µl of 0.4 lipid vesicle mg/ml solution), respectively, to give the same resonance unit (RU) values (i.e., 4000 RU), to ensure the consistent lipid coating). The level of lipid coating for both surfaces was kept at the minimum that is necessary for preventing non-specific adsorption to the sensor chips. This low surface coverage minimised the mass transport effect and kept the total protein concentration (P_0) above the total concentration of protein binding sites on vesicles (M_0). Steady-state SPR measurements were done at the flow rate of 5 ml/min to allow sufficient time for the R values of the association phase to reach near-equilibrium values (R_{eq}). After sensorgrams were obtained for 5 or more different concentrations of each protein within a 10-fold range of K_d , each of the sensorgrams was corrected for refractive index change by subtracting the control surface response from it. Assuming a Langmuir-type binding between the protein (P) and protein binding sites (M) on vesicles (i.e., $P + M \leftrightarrow PM$), R_{eq} values were then plotted versus P_0 , and the K_d value was determined by a nonlinear least-squares analysis of the binding isotherm using an equation, $R_{eq} = R_{max}/(1 + K_d/P_0)$. Each data set was repeated three or more times to calculate average and standard deviation values. For kinetic SPR measurements, the flow rate was maintained at 15 µl/min for both association and dissociation phases. Kinetic SPR data were collected to illustrate relative membrane affinity quantitatively and were not used for K_d determination.

Isothermal titration Calorimetry (ITC)

Microcalorimetric titration measurements were performed in a Microcal Omega isothermal titration calorimeter (Microcal, Northampton, MA, USA). All solutions were degassed under vacuum prior to use. In a typical experiment, 1.33 ml of 20 µM WT or mutant PDZ2 ZO-1 or ZO-2 in 20 mM HEPES, 150 mM NaCl, pH 7.5 was titrated by 20 × 15 µl injections of 200 µM Cx43 peptide. During titration, the injection syringe was rotated at 250 rpm. Time between injections was 5 min. In a blank experiment, heat evolved from dilution was measured by injecting the peptide solution into the sample cell filled with buffer only. This heat of dilution was subtracted from the peptide binding data for the PDZ2 domain. Data were integrated and fitted to an appropriate binding model using the ORIGIN software supplied by Microcal.

Results

The PDZ2 domain of ZO-1 and ZO-2 binds to phosphoinositides in vitro

ZO-1 and -2 contain 3 N-terminal PDZ domains, followed by an SH3, a GuK domain, and a carboxy terminal end that includes an acidic domain and a proline-rich region (Figure 1A). We performed a lipid-overlay assay using PIP strips (nitrocellulose membranes on which various phospholipids are immobilised (Figure 1B) for initial screening of the PDZ domains of ZO-1 and -2. In this assay the lipids are not in a membrane environment and the readout is not quantitative but it is a simple, fast and routinely used assay [31]. A GST-ZO-1 construct containing three PDZ domains (GST-ZO1-PDZ1-3) bound non-selectively to all PtdInsPs and acidic phospholipids, including PtdIns, phosphatidylserine (PS) and phosphatidic acid (PA) (Figure 1B). On the other hand, GST alone did not bind to any phospholipid. The PH domain of LL5 α , known to non-selectively bind PtdInsPs, was used as a positive control (Figure 1B). We then subjected individual PDZ domains to the lipid-overlay assay to determine which PDZ domain contained the PtdInsP-binding site. GST-ZO1-PDZ2 bound PtdInsPs as efficiently as GST-ZO1-PDZ1-3, while GST-ZO1-PDZ1 and GST-ZO1-PDZ3 showed weak to no binding (Figure 1B), indicating that the ZO-1 PDZ2 domain contained the PtdInsP-binding site. Circular dichroism experiments showed that folding of the GST-tagged PDZ3 domain from ZO-1 and ZO-2 was very similar to the folding pattern of GST-ZO-2-PDZ2 (data not shown). Since the PDZ domains of ZO-2 are highly homologous to their counterparts in ZO-1, we also tested if the PDZ domains of ZO-2 bind PtdInsPs. As shown in Figure 1B, the PDZ2 domain of ZO-2 also interacted with several PtdInsPs, although differences can be noticed with the ZO-1 PDZ2 domain, while PDZ1 and PDZ3 did not show significant binding. Moreover, the lack of lipid binding by a construct encompassing the Src Homology (SH3) domain up to the C-terminus (SH3-C) corroborates the notion that PtdInsP binding is restricted to the PDZ2 domain (Figure 1B).

We also performed a more sensitive ELISA assay on commercially available PIP plates. Again, lipids are not in a membrane environment in this assay. GST alone showed no significant affinity to any of the lipids (Figure 1C, blue bars). We observed that both GST-ZO1-PDZ2 and GST-ZO2-PDZ2 bound slightly stronger to PtdIns(3,4) P_2 and PtdIns(3,4,5) P_3 as compared to PtdIns(4,5) P_2 or PtdIns(3,5) P_2 (Figure 1C, red and yellow bars). This indicates that GST-ZO1-PDZ2 and GST-ZO2-PDZ2 have some degree of lipid selectivity and also suggests that the differences between GST-PDZ2-ZO-1 and GST-PDZ2-ZO-2 observed in Fig. 1B do not reflect gross differences in lipid specificity. GST-ZO-2-PDZ1-3 showed some preference for bisphosphoinositides in this assay (Supplementary Figure S1). The pleckstrin homology (PH) domain of phospholipase C δ (PLC δ) was used as a positive control [32], which showed stronger binding to PtdIns(4,5) P_2 than to other phosphoinositides, confirming the validity of the assay (Figure 1C, cyan bars).

To obtain quantitative information about PtdInsP affinity and selectivity of ZO PDZ domains, we measured their binding to PtdInsP-containing vesicles coated onto the L1 sensor chip by SPR analysis. Gel-filtration chromatography showed that both GST-ZO1-PDZ2 and GST-ZO2-PDZ2 form dimers when the monomer concentration was as low as 100 nM (Supplementary Figure S2). Thus, these PDZ domains should exist as dimers under our experimental conditions. We first measured the binding of GST-ZO1-PDZ2 to POPC/POPE/POPS/PtdInsP (37:40:20:3), containing each of seven PtdInsP. Similar to the ELISA assay, sensorgrams from kinetic SPR measurements (Figure 2A) showed that the ZO-1 PDZ-2 domain showed a slight preference for PtdIns(3,4) P_2 binding, followed by PtdIns(3,4,5) P_3 , PtdIns(4,5) P_2 and PtdIns(3,5) P_2 . Monophosphoinositides showed weaker to no binding. A similar pattern was observed with GST-ZO2-PDZ2 (See Supplementary Figure S3A). PDZ1 and PDZ3 domains of ZO-1 and ZO-2 showed no detectable binding. To determine the lipid selectivity of the PDZ2 domains of ZO-1 and ZO-2 more

quantitatively, we determined K_d values for individual vesicles by equilibrium SPR analysis (K_d values are listed in Table I). The apparent affinity of the ZO1 PDZ2 domain for POPC/POPE/POPS/PtdIns(3,4) P_2 vesicles ($K_d = 0.59 \mu\text{M}$) was only 2-fold higher than the value obtained for the ZO-1 PDZ2 domain and POPC/POPE/POPS/PtdIns(4,5) P_2 vesicles ($K_d = 1.3 \mu\text{M}$). This indicates that ZO PDZ2 domains have only a minor degree of lipid selectivity. Therefore, all our ensuing measurements were performed using PtdIns(4,5) P_2 -containing vesicles because PtdIns(4,5) P_2 is a major phosphoinositide that is present in a much higher concentration than PtdIns(3,4) P_2 in mammalian cells. Of note, the latter K_d value is lower (i.e., higher affinity) than that of the GST-tagged full-length syntenin-1 for the same vesicles (see Table 1), indicating that the ZO-1 PDZ-2 domain has PtdIns(4,5) P_2 affinity that is comparable to the tandem PDZ domains of syntenin 1, a well characterised PtdIns(4,5) P_2 interacting protein [24], although the latter does not form domain swapping dimers. Overall, these results show that the ZO-1 and ZO-2 PDZ2 domains display PtdInsP binding with slight lipid selectivity, and that they have relatively high PtdInsP affinity compared with other reported lipid-binding PDZ domains.

Identification of the lipid binding site in the PDZ2 domains of ZO-1 and ZO-2

All structurally characterised PDZ domains have similar structural folds with a canonical peptide binding pocket. Recent reports indicated that PDZ domains containing basic residues on the surface surrounding the peptide-binding groove can interact with anionic lipids, including PtdInsPs [23]. The PDZ2 domains of ZO-1 and ZO-2 are relatively unique among PDZ domains in that they form domain-swapping dimers [23,33]. That is, the dimer is stabilised by extensive symmetric domain swapping of β -strands and the canonical peptide binding pocket is created by elements contributed from both monomers. As shown in Figure 3A, the ZO-1 PDZ2 domain dimer has cationic residues surrounding the peptide binding pocket and these residues are nearly equally contributed from the two monomeric units (i.e., K191, R193, K194, and R201 from the B chain and K246, R251, and K253 from the A chain; A and B chains are arbitrarily defined in Figure 3A). To see if these residues are involved in PtdInsP binding, we mutated them individually to Ala and measured the effects on binding to POPC/POPE/POPS/PtdIns(4,5) P_2 (37:40:20:3) vesicles by SPR analysis. Results are illustrated in Figure 3B and also summarised in Table II. The most dramatic effect was seen with K253A, which is followed by R201A, R251A, and K246A. In fact, we could not determine the K_d values for these mutants because their affinities were too low. These results suggest that R201 from B chain and K246, R251, and K253 from A chain are most directly involved in vesicle binding. Also, the mutations of K191, R193, and K194, which belong to the same B chain as R201, had modest but definite effects on vesicle binding. In contrast, the mutation of R219 that is located remotely from these residues had no effect on vesicle binding. Collectively, these results define a relatively wide lipid binding surface of the ZO-PDZ2 domains containing multiple basic residues. Similar results were obtained from mutational analysis of the ZO2 PDZ2 domain; i.e., R302A and R347A mutations of ZO2 PDZ2 showed similar effects to their ZO1 PDZ2 counterparts, R201A and K246A mutations, respectively (See Supplementary Figure S3B).

Some of these residues would interact directly with the PtdInsP headgroup while others may interact non-specifically with the anionic membrane surface. To distinguish these two types of basic residues, we measured the effects of mutations on binding to POPC/POPE/POPS (40:40:20) vesicles. Notice that K253A, R201A, R251A and K246A had much lower affinities than K191A, R193A and K194A for POPC/POPE/POPS/PtdIns(4,5) P_2 (37:40:20:3) vesicles. For POPC/POPE/POPS (40:40:20) vesicles, however, all these mutants showed comparable affinities (Fig. 3C). This suggests that although all basic residues on the putative lipid-binding surface contribute to the overall binding to anionic membranes, K253, R201, R251 and K246 which are closer to the peptide binding pocket are

more directly involved in PtdInsP headgroup binding than others. On the basis of these results, we performed the docking of a PtdIns(4,5) P_2 molecule to each unit of a ZO1 PDZ2 dimer. Due to the symmetric nature of the dimer, it was postulated that the dimer would form two identical lipid binding sites. The model shown in Figure 3D suggests that the putative PtdInsP-binding site and the peptide-binding site overlap to the extent that two binding processes may be mutually exclusive.

PtdIns and peptide binding are mutually exclusive

The PDZ2 domains of the ZO proteins have been shown to bind the Gap Junction protein connexin43 (Cx43). Binding involves the C-terminal peptide sequence of Cx43 (DDLEI) that fits into the hydrophobic pocket of the PDZ domain [34]. In addition, domain-swapping dimerisation of ZO-1 PDZ2 creates an extended ligand-binding pocket located in PDZ dimer interface [35]. To evaluate the extent of overlap between PtdInsP binding and peptide binding of ZO PDZ2 domains, we investigated the effect of the mutations in the PtdInsP binding site on the peptide binding ability of the ZO-1 PDZ2 domain. We measured by ITC analysis the binding of wild types and mutants of ZO-1 and -2 PDZ2 domains with a peptide, encompassing the C-terminal 20 amino acids of Cx43. The ITC analysis yielded a dissociation constant (K_D) of $\sim 9.9 \mu\text{M}$ for ZO1 and ZO2 PDZ2 domains, which is in good agreement with the value of $15.5 \mu\text{M}$ reported for ZO-1 PDZ2 –[36], with a stoichiometry close to 1 mol peptide/mol PDZ domain (Figure 4A and Table II). This value is also comparable with K_D s determined for other PDZ domains [37]. As summarised in Table II, among ZO1 PDZ2 mutants, R201A and K246A mutants showed no significant binding to the Cx43 peptide while R251A, K253A, and the double-site mutant R251A/K253A had about 2-fold lower peptide affinity than the wild type. In contrast, mutations of R193 and K194, which were found to interact non-specifically with anionic membranes (see above), had little effect on peptide affinity. Likewise, the mutation of R219 that is remote from the lipid binding site had no effect on the peptide binding. Similar results were seen with ZO2 PDZ2 mutations (summarised in Table II). These results support the notion that there is significant overlap between the PtdInsP and peptide binding sites and that the two types of binding are mutually exclusive.

To further corroborate this finding, we performed two additional sets of experiments. First, we examined the effect of the mutations on the association of the GST PDZ2 domain with the Cx43 peptide by a pull-down assay, in which the Cx43 peptide was covalently coupled to CNBr-activated Sepharose (see Materials and Methods). Following incubation with the peptide matrix, 15–20% of the input GST-ZO1-PDZ2 WT was retained on the peptide matrix (Figure 4B, upper left panel, compare lanes 2,6 with lanes 2,6 in right panel which represents the input) while only 5% of the input was retained in case of the R201A (lane 3) and K246A (lane 4). As expected from only a 2-fold difference in peptide affinity, R251A (lane 5), K253A (lane 7), and R251A/K253A (lane 8) behaved similar to the wild type. Non-specific binding was limited to less than 5% of the total protein input, as shown for GST binding (lane 1). GST-ZO2-PDZ2 mutants R302A and R347A also showed strongly reduced interaction with the Cx43 peptide as compared to GST-ZO2-PDZ2 WT (Fig 4B, lower panels).

We then performed an ELISA assay in which the Cx43 peptide immobilised on a plate was incubated with GST-ZO2-PDZ2 WT with or without different PtdInsPs. Figure 5A shows that binding of ZO2 PDZ2 WT to the peptide is inhibited by PtdIns(4,5) P_2 , PtdIns(3,4) P_2 and PtdIns(3,4,5) P_3 in a concentration-dependent manner and to the same extent, in contrast to PS which shows no effect. We also preincubated GST-ZO2-PDZ2 WT with these lipids and subsequently performed a pull down with the Cx43 peptide that was covalently bound to CNBr-activated Sepharose beads. Preincubation of $3 \mu\text{g}$ GST-ZO2-PDZ2 WT with increasing PtdIns(4,5) P_2 concentrations (indicated at the bottom of the panels in Figure 5B)

resulted in a progressively decreasing association of the GST-ZO2-PDZ2 with the Cx43 peptide. Likewise, PtdIns(3,4) P_2 and PtdIns(3,4,5) P_3 inhibited association of GST-ZO2-PDZ2 WT with the Cx43 peptide (Figure 5B), while PS had no effect, confirming the PtdInsP specificity of the PDZ2 domain.

ZO polypeptides colocalise with PtdIns(4,5) P_2 at the plasma membrane

To understand the physiological roles of PtdInsP binding of ZO PDZ2 domains, we analysed the distribution of PtdIns(4,5) P_2 and ZO-1/-2 in different mammalian cells. As described above, we focused on this phospholipid because it is much more abundant in membranes of mammalian cells than PtdIns(3,4) P_2 and PtdIns(3,4,5) P_3 , while the affinity of the ZO PDZ2 domains for PtdIns(4,5) P_2 , PtdIns(3,4) P_2 and PtdIns(3,4,5) P_3 is of the same order of magnitude (Table I).

In sparsely seeded MDCK cells, endogenous ZO-1 and ZO-2 showed differential localisation. That is, ZO-1 exhibited mainly plasma membrane localisation whereas ZO-2 was also distributed in the nucleus and the cytosol, which is consistent with the previous report (Figure 6A) [14]. In these cells, the GFP-tagged PH domain of phospholipase C δ (PH-PLC δ) that has been used as a specific probe for PtdIns(4,5) P_2 [32] was co-localised with endogenous ZO-1 and ZO-2 in the plasma membrane, suggesting that ZO proteins might be localised in the plasma membrane due to their interaction with PtdIns(4,5) P_2 (Fig. 6B). This was further substantiated by co-staining with the 2C11 anti-PtdIns(4,5) P_2 antibody (Fig. 6C), used in earlier studies to detect PtdIns(4,5) P_2 [38,39]. Similarly, immunostaining for PtdIns(4,5) P_2 in MDA-MB 231 breast cancer cells using the 2C11 antibody showed co-localisation with endogenous ZO-1/-2, particularly in plasma membrane extensions (Fig. 6D-E). To see if PtdIns(4,5) P_2 binding is responsible for plasma membrane localisation of ZO-1 and ZO-2, we expressed GFP-tagged ZO-1 or ZO-2 wild type and mutants in MDCK cells. Surprisingly, the R201A mutation that essentially abolished both lipid and peptide binding of the ZO1 PDZ2 domain did not significantly affect the plasma membrane localisation of ZO-1 in MDCK cells (Supplementary Figure S4A). Also, the K253A and R251AK253A mutants, which bind the peptide with reduced affinity but show no lipid binding, were localised at the plasma membrane. Similar data were obtained with ZO-2 (Supplementary Figure S4B). These results suggest that unlike Par-3 [23], lipid binding of ZO-1/-2 is not required per se for its plasma membrane localisation.

Endogenous ZO-2 targets nuclear PtdIns(4,5) P_2 in speckles

It was previously shown that ZO-2 localised to the nucleus in a cell density-dependent manner, where it displayed a speckled distribution [15,18]. Moreover, it has been reported that nuclear PtdIns(4,5) P_2 is concentrated in speckles and nucleoli, and that the PDZ domains of syntenin-2 target these subnuclear structures due to PtdIns(4,5) P_2 interaction [34]. To investigate if ZO-2 is also targeted to nuclear speckles by its ability to bind PtdIns(4,5) P_2 , we studied the subcellular distribution of endogenous ZO-2. For these measurements, MCF7 cells were pretreated with actinomycin D because transcriptional inhibitors such as actinomycin D are known to alter the spatial distribution of speckle proteins into fewer and/or abnormally large clusters [39], which helps to clearly visualise the proteins in nuclear speckles. As shown in Fig. 7A, endogenous ZO-2 showed significant overlap with the 2C11 staining pattern suggesting that ZO-2 localises to nuclear speckles due to its ability to interact with PtdIns(4,5) P_2 .

We then investigated the contribution of ZO-2 to nuclear speckle organisation by knocking down endogenous ZO-2 expression in MCF7 and HeLa cells. Figure 7B shows the partial knock down of ZO-2 using 2 different siRNA molecules, when compared to a control siRNA vector. In our hands, silencing of ZO-2 did not alter the levels of other TJ

components such as occludin or ZO-1, in contrast to an earlier report [40] (Figure 7B). Because complete knock down of ZO-2 appeared to be toxic, we analysed cells with partial knock down of ZO-2. In fact, ZO-2 deficient mice are embryonically lethal [unlike ZO-3^{-/-} mice], fail to complete gastrulation and show reduced cell proliferation at E6.5 and increased apoptosis [41]. Reduction in ZO-2 level in both cells resulted in a dispersed PtdIns(4,5)P₂ staining pattern as observed by 2C11 staining (Figure 7C). These results suggest that ZO-2, similar to syntenin-2 [38], could function as a scaffold in the organisation of nuclear PtdIns(4,5)P₂.

Discussion

The present work shows that the PDZ2 domains of ZO-1 and ZO-2 bind PtdInsPs with relatively high affinity, adding these PDZ domains to an increasing list of PDZ domains that interact with lipids. We and others showed previously that the tandem PDZ domains of syntenin-1 and -2 and the PDZ2 domain of PTPBL2 could bind PtdInsPs with micromolar affinity [24,38,42]. More recently, Wu and coworkers [23] reported that a large subset of mammalian PDZ domains, including PICK1 and another MAGUK protein par-3, are capable of binding PtdInsPs in vitro. In general, membrane-binding proteins and domains contain cationic and/or hydrophobic residues on their membrane-binding surfaces [43]. Thus, PDZ domains with cationic and/or hydrophobic residues on their surfaces may have significant affinity for the membrane containing anionic lipids, including PtdInsP. Indeed, Wu et al. [23] reported that the par-3 PDZ2 domain contained a flat surface rich in cationic residues that were shown to play critical roles in lipid binding and that other PDZ domains containing similar cationic residues also bind to anionic vesicles when measured by a vesicle pelleting assay. They also reported that the PDZ1 domain as well as the PDZ2 domain of ZO-1 and ZO-2 bound anionic vesicles; however, no quantitative data on lipid specificity and affinity were reported. We opted to rigorously characterise lipid binding of PDZ domains of ZO proteins because of the potential physiological significance of the ZO PDZ-lipid interactions. Our quantitative SPR analysis clearly shows the isolated PDZ1 domains of ZO-1 and ZO-2 have very low affinity for anionic membranes and only PDZ2 domains of ZO proteins have relatively high PtdInsP affinity and some degree of PtdInsP selectivity. The reason for this discrepancy may derive from differences in the length of the domain constructs, different experimental conditions, or different sensitivity of measurements.

The PDZ2 domains of the ZO proteins have unique structures among PDZ domains in that they form domain-swapping dimers. However, they share a common trait with other anionic membrane binding PDZ domains including par-3; i.e., they have a cluster of cationic residues, K194, R251, and K253 and R201 and K246, on the same surface surrounding the peptide binding pocket. In particular, K194, R251 and K253 in ZO-1 correspond to K458, R532 and K535 in par-3, respectively, which were reported to be involved in anionic membrane binding. Unlike the par-3 PDZ domain, however, ZO-1/-2 PDZ2 domains have modest PtdInsP selectivity. Also, clear distinction between the cationic residues of ZO1 PDZ2 domain that are involved in PtdInsP binding and that participate in non-specific anionic membrane binding indicates the presence of a well-defined binding pocket for PtdInsPs, as illustrated in our model (see Figure 3D).

Our results also indicate that PtdInsP binding and peptide binding of PDZ2 domains of ZO proteins are mutually exclusive because of a significant overlap of two binding sites. Indeed, binding of PtdInsPs to ZO-1 and ZO-2 PDZ2 domain reduces their interactions with a Cx43 carboxy-terminal peptide. It should be noted that Chen and co-workers [35] reported a weaker interaction between ZO-2 PDZ2 and Cx43 ($K_d \sim 391 \mu\text{M}$) as compared to our data ($\sim 10 \mu\text{M}$). This discrepancy may derive primarily from the different length of peptides used for binding studies. We determined the affinity for ZO-1 as well as ZO-2 PDZ2 in this study

using the same (20aa) Cx43 peptide by ITC. The value of 391 μM was obtained by SPR using a peptide covering the last 9 amino acids of Cx43. Indeed, they reported 15.5 μM K_d for ZO-1 PDZ2 when our 20aa Cx43 peptide was employed. The residues that are critical for ZO-1 PDZ2 binding to Cx43 are conserved in ZO-2 PDZ2 except for Arg367 in ZO-2 PDZ2 and Lys246 in ZO-1 PDZ2. Further, substitution of Lys246 in ZO-1 PDZ2 with an arginine residue only moderately decreases binding to Cx43 peptide ($K_d \sim 68 \mu\text{M}$). Thus, our data showing that both PDZ2 domains of ZO1 and ZO2 have similar peptide affinity are not inconsistent with any reported data.

What are the functional consequences of this PtdInsP binding of ZO PDZ2 domains? Both endogenous ZO1 and ZO2 proteins are found in the plasma membrane although their overall subcellular localisation patterns differ significantly. It has been well documented that PtdIns(4,5) P_2 is the most abundant PtdInsP that is located mainly in the inner plasma membrane [44]. Unlike PtdIns(4,5) P_2 , PtdIns(3,4) P_2 and PtdIns(3,4,5) P_3 are signaling lipids that are formed transiently in response to specific stimuli. Thus, their cellular concentrations are much lower (i.e., >100-fold) than that of PtdIns(4,5) P_2 . This, in conjunction with the fact that ZO PDZ2 domains have much lower affinity for PtdIns(3,4) P_2 and PtdIns(3,4,5) P_3 than the specific effector domains of these lipids (e.g., PH domains), suggest that PtdIns(3,4) P_2 and PtdIns(3,4,5) P_3 binding of ZO PDZ domains may not have significant functional significance [6,7]. Although PtdIns(4,5) P_2 is present at higher concentration than PtdIns(3,4) P_2 and PtdIns(3,4,5) P_3 , there are many plasma membrane-targeting domains that have higher PtdIns(4,5) P_2 affinity than ZO PDZ2 domains and thus they may not be able to compete with other proteins for the plasma membrane pool of PtdIns(4,5) P_2 . Consistent with this notion, lipid binding of ZO PDZ2 domains do not seem to play a significant role in the plasma membrane localisation of ZO proteins. This is consistent with the previous observation that the PDZ domains of ZO-1 (PDZ1–3) were not localised at the plasma membrane [45], in contrast with par-3 for which the lipid binding activity of the PDZ domain is important for its plasma membrane localisation. Thus, the plasma membrane binding of ZO-1 and ZO-2 is more likely to be driven by protein-protein interactions [46]. As such this does not preclude a role for PtdIns(4,5) P_2 in modulating signaling complexes involving these tight junction proteins at the plasma membrane. For instance, it has been proposed that ZO-1 assembles PLC β 3 and connexin43 into a signaling complex through interaction of the third PDZ domain of ZO-1 with PLC β 3 [47] while the second PDZ domain binds to connexin43. As PtdIns(4,5) P_2 hydrolysis upon receptor activation leads to inhibition of connexin43 cell-cell based communication, these interactions allow regulation of gap junction closure by localised fluctuations in PtdIns(4,5) P_2 levels. In that study the authors found no evidence for direct binding of PtdIns(4,5) P_2 to connexin43 but hypothesised that PtdIns(4,5) P_2 regulates junctional communication indirectly through a connexin43-associated protein. We speculate that ZO-1 itself may represent such a rheostat protein: PtdIns(4,5) P_2 interaction with the ZO-1 PDZ2 domain could modify the connexin43 regulatory tail, as PtdIns(4,5) P_2 and connexin binding are mutually exclusive, thereby shutting off gap channel function.

However, our results suggest that the PtdIns(4,5) P_2 binding activity of ZO PDZ2 domains may be important for driving subnuclear localisation of ZO proteins, ZO2 in particular. The presence of an independent nuclear PtdInsP pool and the enzymes responsible for their metabolism is now well established [5]. Recent genetic and biochemical evidence suggests that these lipids are involved in post-transcriptional modification and chromatin-mediated gene regulation. In particular, it has been suggested that nuclear PtdIns(4,5) P_2 , which is enriched in speckles and in the nucleoli [44], might be involved in the regulation of chromatin remodelling and gene transcription. Moreover, nuclear PtdIns(4,5) P_2 seems to regulate pre-mRNA splicing and controls cell growth and proliferation. Our results indicate that ZO2 PDZ2 domain can effectively interact with these nuclear pools of PtdIns(4,5) P_2 .

ZO-2 is colocalised with nuclear PtdIns(4,5) P_2 . Although the exact role of nuclear ZO-2 is still unknown, accumulating evidence indicates that it regulates cell growth, proliferation and apoptosis [22]. For example, Tapia et al. [48] recently reported that ZO-2 translocates to the nucleus at late G1 phase to downregulate cyclin D1 expression, and exits the nucleus during mitosis. We speculate that the transcription regulation activity of nuclear ZO-2 may be controlled by PtdInsP(4,5) P_2 . Our gene knock down experiments also show that ZO-2 is involved in organising PtdIns(4,5) P_2 in nuclear speckles, as reported for syntenin-2 [38].

It has been reported that many PDZ domain-containing proteins serve as scaffolds to organise signaling complexes in the plasma membrane [49]. Our current study on the ZO PDZ2 domains and previous studies on syntenin-2 suggest that these proteins may play the same role in the nucleus and that lipid binding is critical for this role. Although the exact mechanism underlying this potentially important process and its functional consequences await further investigation, our results provide new insight into how cellular functions of PDZ domain-containing proteins can be switched by local environments that modulate the lipid binding of the PDZ domain.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank Dr. E. Mortier for helpful discussions during the course of this project and Dr. L. Van Troys and Dr. G. Hammond for useful advice on the lipid stainings. This work was supported by the Fund for Scientific Research-Flanders (FWO-Vlaanderen), the Concerted Actions Programme of Ghent University (GOA), the Interuniversity attraction poles (IUAP06), the Human Frontier Science Program (HFSP), a NIH grant (GM68849) (for W.C.), and the Catalyst Award from Chicago Biomedical Consortium (for W.C. and H.L.). K.M. was supported by a Postdoctoral Fellowship of the Fund for Scientific Research-Flanders (Belgium) (FWO-Vlaanderen). ER is supported by a fellowship from the research council of Ghent University (BOF).

References

1. Cho W. Building signaling complexes at the membrane. *Sci.STKE*. 2006; 2006:e7.
2. Overduin M, Cheever ML, Kutateladze TG. Signaling with phosphoinositides: better than binary. *Mol.Interv.* 2001; 1:150–159. [PubMed: 14993348]
3. Hammond GR, Schiavo G. Polyphosphoinositol lipids: under-PPIning synaptic function in health and disease. *Dev.Neurobiol.* 2007; 67:1232–1247. [PubMed: 17514716]
4. Wymann MP, Schreiner R. Lipid signalling in disease. *Nat.Rev.Mol.Cell Biol.* 2008; 9:162–176. [PubMed: 18216772]
5. Hammond G, Thomas CL, Schiavo G. Nuclear phosphoinositides and their functions. *Curr.Top.Microbiol.Immunol.* 2004; 282:177–206. [PubMed: 14594218]
6. Payraastre B, Missy K, Giuriato S, Bodin S, Plantavid M, Gratacap M. Phosphoinositides: key players in cell signalling, in time and space. *Cell Signal.* 2001; 13:377–387. [PubMed: 11384836]
7. Toker A. Phosphoinositides and signal transduction. *Cell Mol.Life Sci.* 2002; 59:761–779. [PubMed: 12088277]
8. Gassama-Diagne A, Yu W, ter BM, Martin-Belmonte F, Kierbel A, Engel J, Mostov K. Phosphatidylinositol-3,4,5-trisphosphate regulates the formation of the basolateral plasma membrane in epithelial cells. *Nat.Cell Biol.* 2006; 8:963–970. [PubMed: 16921364]
9. Martin-Belmonte F, Mostov K. Regulation of cell polarity during epithelial morphogenesis. *Curr.Opin.Cell Biol.* 2008; 20:227–234. [PubMed: 18282696]
10. Matter K, Balda MS. Epithelial tight junctions, gene expression and nucleo-junctional interplay. *J.Cell Sci.* 2007; 120:1505–1511. [PubMed: 17452622]
11. Aijaz S, Balda MS, Matter K. Tight junctions: molecular architecture and function. *Int.Rev.Cytol.* 2006; 248:261–298. [PubMed: 16487793]

12. Schneeberger EE, Lynch RD. The tight junction: a multifunctional complex. *Am.J.Physiol Cell Physiol.* 2004; 286:C1213–C1228. [PubMed: 15151915]
13. Ebnet K. Organization of multiprotein complexes at cell-cell junctions. *Histochem.Cell Biol.* 2008; 130:1–20. [PubMed: 18365233]
14. Islas S, Vega J, Ponce L, Gonzalez-Mariscal L. Nuclear localization of the tight junction protein ZO-2 in epithelial cells. *Exp.Cell Res.* 2002; 274:138–148. [PubMed: 11855865]
15. Traweger A, Fuchs R, Krizbai IA, Weiger TM, Bauer HC, Bauer H. The tight junction protein ZO-2 localizes to the nucleus and interacts with the heterogeneous nuclear ribonucleoprotein scaffold attachment factor-B. *J.Biol.Chem.* 2003; 278:2692–2700. [PubMed: 12403786]
16. Gottardi CJ, Arpin M, Fanning AS, Louvard D. The junction-associated protein, zonula occludens-1, localizes to the nucleus before the maturation and during the remodeling of cell-cell contacts. *Proc Natl Acad Sci U S A.* 1996; 93:10779–84. [PubMed: 8855257]
17. Gonzalez-Mariscal L, Ponce A, Alarcon L, Jaramillo BE. The tight junction protein ZO-2 has several functional nuclear export signals. *Exp.Cell Res.* 2006; 312:3323–3335. [PubMed: 16920099]
18. Jaramillo BE, Ponce A, Moreno J, Betanzos A, Huerta M, Lopez-Bayghen E, Gonzalez-Mariscal L. Characterization of the tight junction protein ZO-2 localized at the nucleus of epithelial cells. *Exp.Cell Res.* 2004; 297:247–258. [PubMed: 15194440]
19. Betanzos A, Huerta M, Lopez-Bayghen E, Azuara E, Amerena J, Gonzalez-Mariscal L. The tight junction protein ZO-2 associates with Jun, Fos and C/EBP transcription factors in epithelial cells. *Exp.Cell Res.* 2004; 292:51–66. [PubMed: 14720506]
20. Kavanagh E, Buchert M, Tsapara A, Choquet A, Balda MS, Hollande F, Matter K. Functional interaction between the ZO-1-interacting transcription factor ZONAB/DbpA and the RNA processing factor symplekin. *J.Cell Sci.* 2006; 119:5098–5105. [PubMed: 17158914]
21. Huang HY, Li R, Sun Q, Wang J, Zhou P, Han H, Zhang WH. [LIM protein KyoT2 interacts with human tight junction protein ZO-2-i3]. *Yi.Chuan Xue.Bao.* 2002; 29:953–958. [PubMed: 12645256]
22. Huerta M, Munoz R, Tapia R, Soto-Reyes E, Ramirez L, Recillas-Targa F, Gonzalez-Mariscal L, Lopez-Bayghen E. Cyclin D1 is transcriptionally down-regulated by ZO-2 via an E box and the transcription factor c-Myc. *Mol.Biol.Cell.* 2007; 18:4826–4836. [PubMed: 17881732]
23. Wu H, Feng W, Chen J, Chan LN, Huang S, Zhang M. PDZ domains of Par-3 as potential phosphoinositide signaling integrators. *Mol.Cell.* 2007; 28:886–898. [PubMed: 18082612]
24. Zimmermann P, Meerschaert K, Reekmans G, Leenaerts I, Small JV, Vandekerckhove J, David G, Gettemans J. PIP(2)-PDZ domain binding controls the association of syntenin with the plasma membrane. *Mol.Cell.* 2002; 9:1215–1225. [PubMed: 12086619]
25. Kates, M. Amsterdam: Elsevier; 1986.
26. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Anal.Biochem.* 1976; 72:248–254. [PubMed: 942051]
27. Hammond GR, Dove SK, Nicol A, Pinxteren JA, Zicha D, Schiavo G. Elimination of plasma membrane phosphatidylinositol (4,5)-bisphosphate is required for exocytosis from mast cells. *J.Cell Sci.* 2006; 119:2084–2094. [PubMed: 16687737]
28. Hammond GR, Schiavo G, Irvine RF. Immunocytochemical techniques reveal multiple, distinct cellular pools of PtdIns4P and PtdIns(4,5)P2. *Biochem J.* 2009
29. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. *Proc.Natl.Acad.Sci.U.S.A.* 1979; 76:4350–4354. [PubMed: 388439]
30. Manna D, Albanese A, Park WS, Cho W. Mechanistic basis of differential cellular responses of phosphatidylinositol 3,4-bisphosphate- and phosphatidylinositol 3,4,5-trisphosphate-binding pleckstrin homology domains. *J.Biol.Chem.* 2007; 282:32093–32105. [PubMed: 17823121]
31. Rusten TE, Stenmark H. Analyzing phosphoinositides and their interacting proteins. *Nat Methods.* 2006; 3:251–258. [PubMed: 16554828]

32. Varnai P, Balla T. Visualization of phosphoinositides that bind pleckstrin homology domains: calcium- and agonist-induced dynamic changes and relationship to myo-[3H]inositol-labeled phosphoinositide pools. *J.Cell Biol.* 1998; 143:501–510. [PubMed: 9786958]
33. Fanning AS, Lye MF, Anderson JM, Lavie A. Domain swapping within PDZ2 is responsible for dimerization of ZO proteins. *J.Biol.Chem.* 2007; 282:37710–37716. [PubMed: 17928286]
34. Giepmans BN, Verlaan I, Moolenaar WH. Connexin-43 interactions with ZO-1 and alpha- and beta-tubulin. *Cell Commun.Adhes.* 2001; 8:219–223. [PubMed: 12064592]
35. Chen J, Pan L, Wei Z, Zhao Y, Zhang M. Domain-swapped dimerization of ZO-1 PDZ2 generates specific and regulatory connexin43-binding sites. *EMBO J.* 2008; 27:2113–2123. [PubMed: 18636092]
36. Flores CE, Li X, Bennett MV, Nagy JI, Pereda AE. Interaction between connexin35 and zonula occludens-1 and its potential role in the regulation of electrical synapses. *Proc.Natl.Acad.Sci.U.S.A.* 2008; 105:12545–12550. [PubMed: 18719117]
37. Nourry C, Grant SG, Borg JP. PDZ domain proteins: plug and play! *Sci.STKE.* 2003:RE7. [PubMed: 12709532]
38. Mortier E, Wuytens G, Leenaerts I, Hannes F, Heung MY, Degeest G, David G, Zimmermann P. Nuclear speckles and nucleoli targeting by PIP2-PDZ domain interactions. *EMBO J.* 2005; 24:2556–2565. [PubMed: 15961997]
39. Osborne SL, Thomas CL, Gschmeissner S, Schiavo G. NuclearPtdIns(4,5)P2 assembles in a mitotically regulated particle involved in pre-mRNA splicing. *J.Cell Sci.* 2001; 114:2501–2511. [PubMed: 11559758]
40. Hernandez S, Chavez MB, Gonzalez-Mariscal L. ZO-2 silencing in epithelial cells perturbs the gate and fence function of tight junctions and leads to an atypical monolayer architecture. *Exp.Cell Res.* 2007; 313:1533–1547. [PubMed: 17374535]
41. Xu J, Kausalya PJ, Phua DC, Ali SM, Hossain Z, Hunziker W. Early embryonic lethality of mice lacking ZO-2, but Not ZO-3, reveals critical and nonredundant roles for individual zonula occludens proteins in mammalian development. *Mol.Cell Biol.* 2008; 28:1669–1678. [PubMed: 18172007]
42. Kachel N, Erdmann KS, Kremer W, Wolff P, Gronwald W, Heumann R, Kalbitzer HR. Structure determination and ligand interactions of the PDZ2b domain of PTP-Bas (hPTP1E): splicing-induced modulation of ligand specificity. *J.Mol.Biol.* 2003; 334:143–155. [PubMed: 14596806]
43. Cho W, Stahelin RV. Membrane-protein interactions in cell signaling and membrane trafficking. *Annu.Rev.Biophys.Biomol.Struct.* 2005; 34:119–151. [PubMed: 15869386]
44. Bunce MW, Bergendahl K, Anderson RA. Nuclear PI(4,5)P(2): a new place for an old signal. *Biochim.Biophys.Acta.* 2006; 1761:560–569. [PubMed: 16750654]
45. Reichert M, Muller T, Hunziker W. The PDZ domains of zonula occludens-1 induce an epithelial to mesenchymal transition of Madin-Darby canine kidney I cells. Evidence for a role of beta-catenin/Tcf/Lef signaling. *J.Biol.Chem.* 2000; 275:9492–9500. [PubMed: 10734097]
46. Fanning AS, Little BP, Rahner C, Utepbergenov D, Walther Z, Anderson JM. The unique-5 and –6 motifs of ZO-1 regulate tight junction strand localization and scaffolding properties. *Mol.Biol.Cell.* 2007; 18:721–731. [PubMed: 17182847]
47. van Zeijl L, et al. Regulation of connexin43 gap junctional communication by phosphatidylinositol 4,5-bisphosphate. *J Cell Biol.* 2007; 177:881–91. [PubMed: 17535964]
48. Tapia R, Huerta M, Islas S, vila-Flores A, Lopez-Bayghen E, Weiske J, Huber O, Gonzalez-Mariscal L. Zona occludens-2 inhibits cyclin D1 expression and cell proliferation and exhibits changes in localization along the cell cycle. *Mol.Biol.Cell.* 2009; 20:1102–1117. [PubMed: 19056685]
49. Harris BZ, Lim WA. Mechanism and role of PDZ domains in signaling complex assembly. *J.Cell Sci.* 2001; 114:3219–3231. [PubMed: 11591811]

Fig. 1. Structure and lipid binding properties of ZO PDZ2 domains. (A) Schematic overview of the domain organisation of the ZO-proteins. (B) Lipid-overlay assay of different domains of ZO-1 (human) and ZO-2 (mouse). Left is a schematic view of a lipid blot membrane (PIP-strips™). GST and GST-PH-LL5α were used as negative and positive controls, respectively. (C) ELISA PtdInsP binding assay. Each well of a 'PIP specificity' microtiter plate (Echelon Biosciences) was overlaid with GST, GST ZO-1 PDZ2, GST ZO-2 PDZ2, and GST- PH-PLC-δ1 (positive control). Data represent means $\pm$ STDEV ($n=3$). A.U. = absorbance unit.

Fig. 2.

Measurement of ZO-1 PDZ2 PtdInsP binding by SPR analysis. (A) PtdInsP selectivity of ZO-1 PDZ determined by kinetic SPR measurements. 1 μM of protein was added to POPC/POPE/POPS/PtdInsP (37:40:20:3) vesicles containing 7 different PtdInsPs. (B) Equilibrium SPR binding measurements between ZO-1-PDZ2 and POPC/POPE/POPS/PtdIns(4,5)P₂ (37:40:20:3) vesicles with the protein concentration varied from 0.2 to 2.5 μM . (C) A binding isotherm for ZO-1 PDZ2 and POPC/POPE/POPS/PtdIns(4,5)P₂ (37:40:20:3) vesicles. R_{eq} values from Figure 2B (average of triplicate measurements) were plotted as a function of the ZO-1-PDZ2 concentration. A solid line represents a theoretical curve constructed from R_{max} ($= 1500 \pm 230$) and K_d ($= 1.3 \pm 0.4 \mu\text{M}$) values determined by nonlinear least-squares analysis of the isotherm using an equation: $R_{\text{eq}} = R_{\text{max}} / (1 + K_d/P_0)$. 20 mM HEPES buffer, pH 7.4, with 0.16 M KCl was used for all measurements.

Fig. 3. The putative PtdInsP-binding site of the ZO-1 PDZ2 domain. (A) The structure of ZO-1 PDZ2 domain dimer. The structure (PDB id: 2RCZ) is generated by Pymol and shown in cartoon representation with basic residues surrounding the putative peptide-binding groove (red arrow) shown in space-filling representation. Two monomeric units of the dimer are shown in green (A) and blue (B), respectively. A and B chains are arbitrarily defined for illustration. (B) Effects of mutations of basic residues on binding of the ZO-1 PDZ2 dimer to POPC/POPE/POPS/PtdIns(4,5)P₂ (37:40:20:3) vesicles were measured by kinetic SPR analysis. Protein concentrations were kept at 1 μ M. K_d values were determined by equilibrium SPR analysis as shown in Figure 2B and 2C and listed in Table II. (C) Effects of

mutations of basic residues on binding of the ZO-1 PDZ2 dimer to POPC/POPE/POPS (40:40:20) vesicles measured by kinetic SPR analysis. Protein concentrations were kept at 1 μ M. (D) A hypothetical model of the ZO1-PDZ2- PtdIns(4,5)P₂ complex. One PtdIns(4,5)P₂ molecule is manually docked into each monomeric unit on the basis of our mutational analysis and the final conformation was determined through energy minimisation. Notice that in this model the PtdIns(4,5)P₂ head group partially blocks the entry to the putative peptide binding pocket that is outlined in red. The ZO1 PDZ2 dimer is rotated 45° degrees horizontally from Figure 3A to better illustrate the potential overlap of binding sites for PtdIns(4,5)P₂ and a peptide. The approximate location of the membrane-water interface is shown as a cyan line.

Fig. 4.

Peptide binding properties of ZO PDZ2 domains and mutants therein. (A) ITC titration of WT ZO PDZ2 domains with the C-terminal peptide (20 amino acids) of connexin43. Corrected raw heat data (top panel) and a binding isotherm (bottom panel) generated by plotting the area under the peak against the molar ratio of the peptide added to the PDZ domain are shown. (B) Data from pull down experiments measuring the binding of GST-ZO1 PDZ2 WT and mutants (upper panels) or GST-ZO2 PDZ2 WT and mutants (lower panels) to the C-terminal peptide of connexin43 covalently bound to cyanogen bromide (CNBr)-activated Sepharose. GST-ZO2 PDZ2 WT is also shown. The right panel shows the Coomassie staining of the same volume of aliquots from individual proteins.

Fig. 5.

Lipid and peptide binding to ZO PDZ2 domains are mutually exclusive. (A) ELISA peptide binding assay showing that PtdInsPs compete with the Cx43 peptide for interaction with the ZO2 PDZ2 domain. Each well of a microtiter plate was coated with 1.0 μg Cx43 peptide and incubated with 1 μM GST or GST-tagged ZO-2 PDZ2 WT with or without pre-incubation with different PtdInsPs and PS (negative control). Data shown are representative of duplicate assays, each performed in triplicate. (RCU= relative colorimetric units). (B) Results from a pull-down assay measuring the binding of 3 μg GST-ZO2 PDZ2 WT to the C-terminal peptide of Cx43 covalently bound to CNBr-activated Sepharose with or without preincubation with different phospholipid liposomes at the indicated concentrations.

Fig. 6. ZO-proteins co-localise with PtdIns(4,5)P₂. (A) Localisation of endogenous ZO-1 and ZO-2 in MDCK cells. Notice that ZO-1 exhibits mainly plasma membrane localisation whereas ZO-2 shows nuclear staining and cytoplasmic/membrane staining. (B) Endogenous ZO-1 and ZO-2 mark out areas where GFP-PH-PLCδ is localised. Nuclear ZO-2 is less clear because of focus on the plasma membrane. (C) Staining of MDCK cells for ZO-1/PtdIns(4,5)P₂ and ZO-2/PtdIns(4,5)P₂ with 2C11 antibody. (D–E) PtdIns(4,5)P₂ staining reveals co-localisation with endogenous ZO-2 (D) and ZO-1 (E) in polarised MDA-MB 231 breast cancer cells. Scale bar = 10μm.

Fig. 7.

Endogenous ZO-2 localises in nuclear speckles containing PtdIns(4,5) P_2 that disperse upon ZO-2 expression knock down. (A) MCF7 cells treated with 1 μ g/ml actinomycin D and stained for PtdIns(4,5) P_2 with 2C11 antibody. Scale bar = 10 μ m. (B) Western blot analysis of total cell extracts from MCF7 cells (left panels) or HeLa cells (right panels), treated with a control siRNA or two independent siRNAs targeting ZO-2. Actin is used as a loading control. (C) Images of MCF7 cells and HeLa cells transfected with a control siRNA or an siRNA targeting ZO-2 and treated with actinomycin D. Speckle intensity is reduced and speckles appear to have desintegrated. The nuclear PtdIns(4,5) P_2 pattern was visualised using 2C11 antibody. Scale bar = 10 μ m.

Table I

Membrane binding parameters of ZO PDZ2 domains determined from equilibrium SPR analysis.

Lipids	$K_d(\mu\text{M})^a$		
	GST-ZO1-PDZ2	GST-ZO2-PDZ2	GST-Syntenin1 ^c
POPC/POPE/POPS/PtdIns(3,4)P ₂ (37:40:20:3)	0.59 ± 0.13	1.2 ± 0.44	NM ^b
POPC/POPE/POPS/PtdIns(3,4,5)P ₃ (37:40:20:3)	1.0 ± 0.30	NM ^b	NM ^b
POPC/POPE/POPS/PtdIns(3,5)P ₂ (37:40:20:3)	1.2 ± 0.49	NM ^b	NM ^b
POPC/POPE/POPS/PtdIns(4,5)P ₂ (37:40:20:3)	1.3 ± 0.30	NM ^b	2.0 ± 0.59

^a Values represent the mean and standard deviation from triplicate measurements. All measurements were performed in 20 mM HEPES, pH 7.4, containing 0.16 M KCl.

^b Not measured

^c Full-length syntenin-1 containing two PDZ domains.

Table II

Membrane and peptide binding parameters of ZO PDZ2 domain mutants.

Proteins	$K_d(\mu\text{M})$	
	POPC/POPE/POPS/PtdIns(4,5) P_2^a (37:40:20:3)	Connexin43 peptide ^b
ZO-1 PDZ2 WT	1.3 ± 0.30	9.9 ± 1.3
ZO-1 PDZ2 K191A	NM ^c	NM ^c
ZO-1 PDZ2 R193A	NM ^c	11 ± 2.1
ZO-1 PDZ2 K194A	2.1 ± 0.5	12 ± 1.6
ZO-1 PDZ2 R201A	ND ^d	ND ^d
ZO-1 PDZ2 R219A	NM ^c	11 ± 1.6
ZO-1 PDZ2 K246A	10 ± 5	ND ^d
ZO-1 PDZ2 R251A	15 ± 9	19 ± 3.4
ZO-1 PDZ2 K253A	ND ^d	22 ± 3.6
ZO-1 PDZ2 R251AK253A	ND ^d	21 ± 3.2
ZO-2 PDZ2 WT	2.6 ± 0.7	9.9 ± 1.2
ZO-2 PDZ2 R302A	ND ^d	ND ^d
ZO-2 PDZ2 R347A	20 ± 12	ND ^d

^aValues represent the mean and standard deviation from triplicate SPR measurements. All measurements were performed in 20 mM HEPES, pH 7.4, containing 0.16 M KCl.

^bValues are representative of duplicate ITC assays. All measurements were performed in 20mM HEPES,pH 7.4, containing 0.15 M NaCl.

^cNot measured

^dNot detectable.